No clinical prediction model for late-onset cancer therapy-related cardiac dysfunction is currently both at low risk of bias and validated for use across all adolescent and young adult cancer survivors, according to a systematic review published in Cardio-Oncology.
Survivors of adolescent and young adult cancer, defined as individuals diagnosed between 15 and 39 years of age, face risks of developing late-onset cancer therapy-related cardiac dysfunction years after concluding therapy. This therapy-induced cardiac complication can subsequently progress to heart failure, yet whether any available risk prediction tool applies reliably across this survivor population has remained uncertain.
To evaluate the existing predictive literature, a research team led by Louise Guolla, Paul C. Nathan, and colleagues conducted a systematic review to identify prediction models for late-onset cardiac dysfunction and evaluate their applicability to adolescent and young adult cancer survivors. The research protocol for the investigation was registered with PROSPERO under registration code CRD42023458516.
The authors searched multiple electronic databases to locate models developed or validated in cancer survivors of any age who were at least one year past their cancer diagnosis. Eligible publications were full-text English-language studies that utilized real-life patient datasets alongside routine clinical variables to predict late-onset dysfunction, with bias and applicability evaluated using the Prediction model Risk of Bias Assessment Tool.
Screening of 12,740 records yielded 22 studies that developed or validated 64 distinct prediction models for late-onset cardiac dysfunction. Among these models, 54.7 percent focused on predicting symptomatic cardiac dysfunction, drawing on a pooled population of 139,765 cancer survivors of whom 9.4 percent were adolescent and young adult patients.
Across the identified tools, patient age, sex, anthracycline exposure, and chest radiation emerged as the most frequently incorporated clinical predictors. However, 84.4 percent of the models were judged to carry a high risk of bias, an evaluation frequently resulting from insufficient reporting of underlying statistical methods.
Only two studies developed models, comprising eight models in total, that demonstrated both a low risk of bias and high applicability to adolescent and young adult cancer survivors. Crucially, neither of these models had undergone validation across the entire age range or the diverse disease spectrum characteristic of adolescent and young adult oncology.
The investigators concluded that existing prediction models for late-onset chemotherapy-related cardiac dysfunction remain limited by methodological bias and lack effective validation across most adolescent, young adult, and adult groups. The authors noted that future investigative efforts should focus on validating existing prediction models across diverse populations categorized by patient age, specific cancer diagnosis, and geographic setting.
Subject of Research: Prediction models for late-onset cancer therapy-related cardiac dysfunction in adolescent and young adult cancer survivors
Article Title: Can we predict late risk of cancer-therapy related cardiac dysfunction including heart failure in survivors of adolescent and young adult cancer? A systematic review
Article References: Guolla, L., Mullen, J. C., Fajardo, A. F., Stewart, B., Kakar, K., Mbuagbaw, L., Ma, J., Thabane, L., Gupta, S., & Nathan, P. C. (2026). Can we predict late risk of cancer-therapy related cardiac dysfunction including heart failure in survivors of adolescent and young adult cancer? A systematic review. Cardio-Oncology. https://doi.org/10.1186/s40959-026-00556-1
Image Credits: AI Generated
DOI: 10.1186/s40959-026-00556-1
Keywords: cardio-oncology, cancer survivors, adolescent and young adult cancer, cardiac dysfunction, heart failure, risk prediction models, anthracyclines, systematic review, predict, late, risk, cancer-therapy
News Source: Nathaniel Bowman. (November 10, 2026). Heart Dysfunction Risk Models Lack Validation Across Young Cancer Survivors. Scienmag.



